Supplementary Figure S1

Slides:

Advertisements

Similar presentations

Creating a Box-and-Whisker Plot O To create your own box-and-whisker plot, you must first find the following values. Lowest Value Lower Quartile Median.

Advertisements

Box and Whisker Plots Example: Comparing two samples.

R&R Homework Statgraphics “Range Method”. DATA OperatorPartTrialMeasure B B B B B B326.5 B B B C

Creating a Box-and-Whisker Plot O To create your own box-and-whisker plot, you must first find the following values. Lowest Value Lower Quartile Median.

From: Anesthetic Technique for Radical Prostatectomy Surgery Affects Cancer Recurrence:A Retrospective Analysis Anesthes. 2008;109(2): doi: /ALN.0b013e31817f5b73.

Preprocedural high-sensitive troponin predicts survival after transcatheter aortic valve implantation (TAVI) Derk Frank, Sophia Stark, Matthias Lutz,

C Supplemental Figure S2.. C Supplemental Figure S2.

Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),

UK Renal Registry 10th Annual Report 2007

For a copy of the poster:

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

UK Renal Registry 18th Annual Report

Supplementary Figure 1 CD45 CD14 FSC CD123 HLA-DR CD11c Lineage

Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer C.E. Henry, C. Emmanuel, N.

Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.

Supplementary Figure 1 Representative images of neuroendocrine liver metastases in a non-contrast, low-attenuation CT scan (A), with lesion delineated.

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer Martin Reck, MD, PhD, Normand Blais,

CHAPTER 11: Haemodialysis Practices

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma Liver Cancer 2017;6: DOI: /

Effect of Measurement Error on SPC

Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Medical Nutrition Therapy for Chronic Kidney Disease Improves Biomarkers and Slows Time to Dialysis Desirée de Waal, MS, RD, CD, FAND, Emily Heaslip,

Benefit of immediate revascularization in women with critical limb ischemia in an intention-to-treat analysis Jana Ortmann, MD, Eveline Nüesch, PhD,

Comparison of General Anesthesia and Conscious Sedation During Computed Tomography–Guided Radiofrequency Ablation of T1a Renal Cell Carcinoma Hae Jin.

Tutorial 9 Suppose that a random sample of size 10 is drawn from a normal distribution with mean 10 and variance 4. Find the following probabilities:

Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study Thomas K. Eigentler, Ulrike Leiter, Hans-Martin Häfner,

A Phase II Study of PF in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207 Paul Wheatley-Price, MBChB, MD, Quincy Chu,

Molecular Subtypes of Non-muscle Invasive Bladder Cancer

Survival after resection of synchronous non–small cell lung cancer

Volume 3, Issue 9, Pages e421-e430 (September 2016)

Resection of Intraabdominal Tumors With Cavoatrial Extension Using Deep Hypothermic Circulatory Arrest Christopher Lau, MD, Padraic O’Malley, MD, Mario.

Ioannis Koulouridis, MD, MS, Lori Lyn Price, MAS, Nicolaos E

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer Johan F. Vansteenkiste, MD, PhD, Jean-Luc.

Mintu P. Turakhia et al. JACEP 2016;2:

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based.

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial Kenneth S. Thress, PhD, Vivien.

Volume 65, Issue 2, Pages (February 2004)

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Standard versus Dose-Intensified Chemotherapy with Sequential Reinfusion of Hematopoietic Progenitor Cells in Small Cell Lung Cancer Patients with Favorable.

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III.

Eric S. Weiss, MD, MPH, Jeremiah G. Allen, MD, Christian A

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for.

A Meta-Analysis of Postoperative Radiotherapy for Thymic Carcinoma

Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome Luisella Righi, MD, PhD, Tiziana Vavalà, MD, Ida.

Combined data from RISC (n=3,024) and San Raffaele dataset (n=1,067)

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),

Kaplan-Meier One Minus Survival plot showing cumulative progression to clinical arthritis for patients with clinically suspect arthralgia divided in four.

Fig. 1. Kaplan-Meier curves for PFS and OS

European Urology Oncology

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Supplementary Figure S5

Time to cessation of rectal bleeding in patients with frank bleeding at baseline. Time to cessation of rectal bleeding in patients with frank bleeding.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Figure 1. Kaplan Meier curves showing crude product limit survival estimates and 95% confidence intervals for time to ... Figure 1. Kaplan Meier curves.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J

Presentation transcript:

Supplementary Figure S1 Supplementary Figure S1. Waterfall Plot Chart: Tumor Size Variation(%) from Baseline during YS110 Administration in First Cycle 55.6 50.0 27.6 26.3 21.3 20.2 19.3 16.2 14.8 11.3 11.2 8.7 8.5 6.7 6.1 4.0 2.3 2.1 2.0 0.0 -0.5 -1.3 -2.4 -2.6 -7.5 -20 -10 10 20 30 40 50 60 0308 0203 0204 0401 0109 0110 0102 0205 0101 0103 0111 0409 0501 0108 0403 0306 0405 0107 0503 0402 0304 0302 0301 0104 0502 Percent Change from Baseline in First Cycle Unit :　% PD 12cases SD 13cases * † ** (47) (59) (39) (42) (43) (40) (41) (83) (35) (98) (184) (273) (33) (230) (399) (223) (258) (57) * : Mesothelioma Subject ** : Renal cell carcinoma † : urothelial carcinoma ( ) : PFS (days)

Supplementary Figure S2. Kaplan meier Plot : Progression-Free Survival Group : 0.0 0.2 0.4 0.6 0.8 1.0 28 56 84 112 140 168 196 224 252 280 308 336 364 392 All Groups: 26cases* * : one case No.0106(mesothelioa) eligible for PFS analysis was involved, therefore, total cases were 26 cases. Survival Distribution Function : Censored Progression Free Survival Time (days) Quartiles Estimate Upper Group Quartiles Estimate Lower All Groups 75 184 57 258 50 43 40 59 25 39 15 41 Tow-Sided 95% Confidence Interval